Aptevo Therapeutics Faces Delisting Notice
Ticker: APVO · Form: 8-K · Filed: May 22, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | May 22, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-rule, regulatory
Related Tickers: APVO
TL;DR
APVO got a delisting notice, might be in trouble.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on May 22, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes other events and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Seattle, Washington.
Why It Matters
This filing indicates potential issues with Aptevo Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to its operations and investors.
Key Numbers
- 001-37746 — Commission File Number (Identifies the company's SEC filing history.)
- 81-1567056 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- May 22, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Seattle, Washington (location) — Principal Executive Offices
- 206-838-0500 (phone_number) — Business Phone
FAQ
What specific listing rule or standard has Aptevo Therapeutics Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Aptevo Therapeutics Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule has been issued.
What are the implications of this notice for Aptevo Therapeutics Inc.'s stock trading?
A notice of delisting typically means the company is at risk of being removed from its stock exchange, which could lead to increased volatility and potential trading halts.
When was this 8-K form filed?
This 8-K form was filed on May 22, 2025.
What is the primary business of Aptevo Therapeutics Inc. according to the filing?
The filing lists Aptevo Therapeutics Inc. under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where are Aptevo Therapeutics Inc.'s principal executive offices located?
Aptevo Therapeutics Inc.'s principal executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 22, 2025 regarding Aptevo Therapeutics Inc. (APVO).